FDA approves gene therapy for severe leukocyte adhesion deficiency-I, a rare immune disorder
March 27, 2026
March 27, 2026
LOS ANGELES, California, March 27 -- The University of California posted the following news release:
* * *
FDA approves gene therapy for severe leukocyte adhesion deficiency-I, a rare immune disorder
*
Key takeaways
* Severe leukocyte adhesion deficiency-I is a rare genetic disease that prevents white blood cells from functioning normally, leaving affected children susceptible to recurrent, life-threatening infections.
* * *
FDA approves gene therapy for severe leukocyte adhesion deficiency-I, a rare immune disorder
*
Key takeaways
* Severe leukocyte adhesion deficiency-I is a rare genetic disease that prevents white blood cells from functioning normally, leaving affected children susceptible to recurrent, life-threatening infections.